Home Table of Contents

§ 21-2C-05. Disclosure of conflict of interest

West's Annotated Code of MarylandHealth--GeneralEffective: July 1, 2019

West's Annotated Code of Maryland
Health--General
Title 21. Food, Drugs, and Cosmetics (Refs & Annos)
Subtitle 2c. Prescription Drug Affordability Board (Refs & Annos)
Effective: July 1, 2019
MD Code, Health - General, § 21-2C-05
§ 21-2C-05. Disclosure of conflict of interest
Currentness
In general
(a)(1) A conflict of interest shall be disclosed:
(i) By the Board when hiring Board staff;
(ii) By the appointing authority when appointing members and alternate members to the Board and members to the Stakeholder Council; and
(iii) By the Board, when a member of the Board is recused in any final decision resulting from a review of a prescription drug product.
(2) A conflict of interest shall be disclosed:
(i) In advance of the first open meeting after the conflict is identified; or
(ii) Within 5 days after the conflict is identified.
Posted on website
(b)(1) A conflict of interest disclosed under subsection (a) of this section shall be posted on the website of the Board unless the chair of the Board recuses the member from any final decision resulting from a review of a prescription drug product.
(2) A posting under paragraph (1) of this subsection shall include the type, nature, and magnitude of the interests of the member involved.

Credits

Added by Acts 2019, c. 692, § 1, eff. July 1, 2019.
MD Code, Health - General, § 21-2C-05, MD HEALTH GEN § 21-2C-05
Current through legislation effective through April 9, 2023, from the 2024 Regular Session of the General Assembly. Some statute sections may be more current, see credits for details.
End of Document